Literature DB >> 24496747

PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.

Jianqiao Xiao1, Seung-Tae Lee, Yuanyuan Xiao, Xiaomei Ma, E Andres Houseman, Ling-I Hsu, Ritu Roy, Margaret Wrensch, Adam J de Smith, Anand Chokkalingam, Patricia Buffler, John K Wiencke, Joseph L Wiemels.   

Abstract

While the cytogenetic and genetic characteristics of childhood acute lymphoblastic leukemias (ALL) are well studied, less clearly understood are the contributing epigenetic mechanisms that influence the leukemia phenotype. Our previous studies and others identified gene mutation (RAS) and DNA methylation (FHIT) to be associated with the most common cytogenetic subgroup of childhood ALL, high hyperdiploidy (having five more chromosomes). We screened DNA methylation profiles, using a genome-wide high-dimension platform of 166 childhood ALLs and 6 normal pre-B cell samples and observed a strong association of DNA methylation status at the PTPRG locus in human samples with levels of PTPRG gene expression as well as with RAS gene mutation status. In the 293 cell line, we found that PTPRG expression induces dephosphorylation of ERK, a downstream RAS target that may be critical for mutant RAS-induced cell growth. In addition, PTPRG expression is upregulated by RAS activation under DNA hypomethylating conditions. An element within the PTPRG promoter is bound by the RAS-responsive transcription factor RREB1, also under hypomethylating conditions. In conclusion, we provide evidence that DNA methylation of the PTPRG gene is a complementary event in oncogenesis induced by RAS mutations. Evidence for additional roles for PTPR family member genes is also suggested. This provides a potential therapeutic target for RAS-related leukemias as well as insight into childhood ALL etiology and pathophysiology.
© 2014 UICC.

Entities:  

Keywords:  DNA methylation; PTPRG; RAS; childhood acute lymphoblastic leukemia

Mesh:

Substances:

Year:  2014        PMID: 24496747      PMCID: PMC4776754          DOI: 10.1002/ijc.28759

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells.

Authors:  Yutaka Arimura; Junji Yagi
Journal:  Sci Signal       Date:  2010-08-31       Impact factor: 8.192

2.  High density DNA methylation array with single CpG site resolution.

Authors:  Marina Bibikova; Bret Barnes; Chan Tsan; Vincent Ho; Brandy Klotzle; Jennie M Le; David Delano; Lu Zhang; Gary P Schroth; Kevin L Gunderson; Jian-Bing Fan; Richard Shen
Journal:  Genomics       Date:  2011-08-02       Impact factor: 5.736

3.  Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

Authors:  Michaël Porcu; Maria Kleppe; Valentina Gianfelici; Ellen Geerdens; Kim De Keersmaecker; Marco Tartaglia; Robin Foà; Jean Soulier; Barbara Cauwelier; Anne Uyttebroeck; Elizabeth Macintyre; Peter Vandenberghe; Vahid Asnafi; Jan Cools
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

4.  Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.

Authors:  Rinesh Godfrey; Deepika Arora; Reinhard Bauer; Sabine Stopp; Jörg P Müller; Theresa Heinrich; Sylvia-Annette Böhmer; Markus Dagnell; Ulf Schnetzke; Sebastian Scholl; Arne Östman; Frank-D Böhmer
Journal:  Blood       Date:  2012-03-20       Impact factor: 22.113

5.  Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Joseph L Wiemels; Michelle Kang; Jeffrey S Chang; Lily Zheng; Carina Kouyoumji; Luoping Zhang; Martyn T Smith; Ghislaine Scelo; Catherine Metayer; Patricia Buffler; John K Wiencke
Journal:  Blood Cells Mol Dis       Date:  2010-08-05       Impact factor: 3.039

6.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

7.  Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.

Authors:  Eddy H J van Roon; Noël F C C de Miranda; Merlijn P van Nieuwenhuizen; Emile J de Meijer; Marjo van Puijenbroek; Pearlly S Yan; Tim H-M Huang; Tom van Wezel; Hans Morreau; Judith M Boer
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

8.  Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.

Authors:  Marco Della Peruta; Giovanni Martinelli; Elisabetta Moratti; Davide Pintani; Marzia Vezzalini; Andrea Mafficini; Tiziana Grafone; Ilaria Iacobucci; Simona Soverini; Marco Murineddu; Fabrizio Vinante; Cristina Tecchio; Giovanna Piras; Attilio Gabbas; Maria Monne; Claudio Sorio
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

9.  FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.

Authors:  Patrick Chang; Michelle Kang; Anny Xiao; Jeffrey Chang; James Feusner; Patricia Buffler; Joseph Wiemels
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

10.  Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis.

Authors:  Hamid Hashemi; Michael Hurley; Anna Gibson; Veera Panova; Viktoria Tchetchelnitski; Alastair Barr; Andrew W Stoker
Journal:  Mol Cell Neurosci       Date:  2010-11-26       Impact factor: 4.314

View more
  8 in total

1.  Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.

Authors:  Julie Irving; Elizabeth Matheson; Lynne Minto; Helen Blair; Marian Case; Christina Halsey; Isabella Swidenbank; Frida Ponthan; Renate Kirschner-Schwabe; Stefanie Groeneveld-Krentz; Jana Hof; James Allan; Christine Harrison; Josef Vormoor; Arend von Stackelberg; Cornelia Eckert
Journal:  Blood       Date:  2014-09-24       Impact factor: 22.113

Review 2.  Receptor-type protein tyrosine phosphatases in cancer.

Authors:  Yu Du; Jennifer R Grandis
Journal:  Chin J Cancer       Date:  2014-10-17

3.  A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.

Authors:  J L Wiemels; A J de Smith; J Xiao; S-T Lee; M O Muench; M E Fomin; M Zhou; H M Hansen; A Termuhlen; C Metayer; K M Walsh
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

4.  PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Authors:  Julia Drube; Thomas Ernst; Markus Pfirrmann; Benadict Vincent Albert; Sebastian Drube; Daniela Reich; Anne Kresinsky; Kathrin Halfter; Claudio Sorio; Christian Fabisch; Andreas Hochhaus; Frank-D Böhmer
Journal:  Oncotarget       Date:  2018-01-15

5.  Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.

Authors:  Mohamed A Ismail; Muthanna Samara; Ali Al Sayab; Mohamed Alsharshani; Mohamed A Yassin; Govindarajulu Varadharaj; Marzia Vezzalini; Luisa Tomasello; Maria Monne; Hisham Morsi; M Walid Qoronfleh; Hatem Zayed; Richard Cook; Claudio Sorio; Helmout Modjtahedi; Nader I Al-Dewik
Journal:  Mol Genet Genomic Med       Date:  2020-07-23       Impact factor: 2.183

Review 6.  The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer.

Authors:  Christian Boni; Claudio Sorio
Journal:  Front Cell Dev Biol       Date:  2022-01-05

7.  A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

Authors:  Marzia Vezzalini; Andrea Mafficini; Luisa Tomasello; Erika Lorenzetto; Elisabetta Moratti; Zeno Fiorini; Tessa L Holyoake; Francesca Pellicano; Mauro Krampera; Cristina Tecchio; Mohamed Yassin; Nader Al-Dewik; Mohamed A Ismail; Ali Al Sayab; Maria Monne; Claudio Sorio
Journal:  J Hematol Oncol       Date:  2017-06-21       Impact factor: 17.388

Review 8.  Transcription Factor RREB1: from Target Genes towards Biological Functions.

Authors:  Ya-Nan Deng; Zijing Xia; Peng Zhang; Samina Ejaz; Shufang Liang
Journal:  Int J Biol Sci       Date:  2020-02-21       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.